Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT04968509

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04968509
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04968509. Randomized; single masking; primary purpose treatment. Start 2024-03-22 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis
Condition
Aortic Stenosis
Intervention (Drug)
PCSK9 inhibitors and statins with or without ezetimibe
Intervention (Drug)
Statins with or without ezetimibe
Lead sponsor
Beijing Anzhen Hospital (class: other)
Collaborator
Beijing Municipal Health Commission (class: other government)

Record details

Record id
cardio:ct-nct04968509
Content hash
c4301892cf755d77d45591023e0aed0a27783c1def88e61fa798f57c445298c4